Cargando…

Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes

SIMPLE SUMMARY: Despite the approval of new targeted therapies for pancreatic neuroendocrine tumors (PanNETs) over the past decades, the early identification of resistant tumors remains the major challenge, mainly because clear signs of tumor shrinkage are rarely achieved by imaging assessment. Star...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cella, Chiara Alessandra, Spada, Francesca, Berruti, Alfredo, Bertolini, Francesco, Mancuso, Patrizia, Barberis, Massimo, Pisa, Eleonora, Rubino, Manila, Gervaso, Lorenzo, Laffi, Alice, Pellicori, Stefania, Radice, Davide, Zorzino, Laura, Calleri, Angelica, Funicelli, Luigi, Petralia, Giuseppe, Fazio, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497075/ https://www.ncbi.nlm.nih.gov/pubmed/36139632 http://dx.doi.org/10.3390/cancers14184471

Ejemplares similares

SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view
por: Spada, F., et al.
Publicado: (2020)

Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single‐center retrospective analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE)
por: Laffi, Alice, et al.
Publicado: (2023)

A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3)
por: Laffi, Alice, et al.
Publicado: (2021)

Nodal Merkel Cell Carcinoma with Unknown Primary Site and No Distant Metastasis: A Single-Center Series
por: Fazio, Nicola, et al.
Publicado: (2022)

Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management
por: Spada, Francesca, et al.
Publicado: (2021)

Reply to comments on ‘COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)’
por: Fazio, Nicola, et al.
Publicado: (2021)

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study
por: Fazio, Nicola, et al.
Publicado: (2021)

Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal
por: Gervaso, Lorenzo, et al.
Publicado: (2021)

Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer
por: Cella, Chiara A., et al.
Publicado: (2023)

Corrigendum to ‘Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study’ [European Journal of Cancer 154 (2021) 246-252]
por: Fazio, Nicola, et al.
Publicado: (2022)

The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: a case series and literature review
por: Zagami, Paola, et al.
Publicado: (2020)

Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment
por: Vitali, Eleonora, et al.
Publicado: (2020)

Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs
por: Laffi, Alice, et al.
Publicado: (2023)

If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma
por: Mancuso, Patrizia, et al.
Publicado: (2010)

Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
por: Orecchioni, Stefania, et al.
Publicado: (2018)

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors
por: Berardi, Rossana, et al.
Publicado: (2017)

Emerging use of everolimus in the treatment of neuroendocrine tumors
por: Gajate, Pablo, et al.
Publicado: (2017)

Endocrine and Neuroendocrine Tumors: A Special Issue
por: Berruti, Alfredo, et al.
Publicado: (2022)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
por: Gelsomino, Fabio, et al.
Publicado: (2020)

Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
por: Peri, Marta, et al.
Publicado: (2020)

Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
por: Oberstein, Paul E., et al.
Publicado: (2012)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2019)

Paradoxic effects of metformin on endothelial cells and angiogenesis
por: Dallaglio, Katiuscia, et al.
Publicado: (2014)

A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
por: Hasic Telalovic, Jasminka, et al.
Publicado: (2021)

Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs
por: Lenotti, Elisa, et al.
Publicado: (2021)

Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches
por: Lania, Andrea, et al.
Publicado: (2021)

Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
por: Cen, Putao, et al.
Publicado: (2012)

Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms
por: Kurita, Yusuke, et al.
Publicado: (2022)

Intermittent everolimus administration for malignant insulinoma
por: Baratelli, Chiara, et al.
Publicado: (2014)

Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms
por: Cella, Chiara Alessandra, et al.
Publicado: (2023)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

Metachronous Testicular Metastases from Merkel Cell Carcinoma (MCC): A Case Report and Literature Review
por: Laffi, Alice, et al.
Publicado: (2022)

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis
por: Fazio, Nicola, et al.
Publicado: (2017)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors
por: Caruso, Damiano, et al.
Publicado: (2022)

Diagnostic Performance and Cell Count of EBUS–TBNA Needle Gauges: A Prospective Trial
por: Guarize, Juliana, et al.
Publicado: (2023)

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
por: Signorovitch, James, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e4us6l894ve5n4i8ip7hb0bbnd